Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EPPIC-Net EN21-01 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of 80 mg Daily of NRD135S.E1 Versus Placebo in Adult and Elderly Participants With Painful Diabetic Peripheral Neuropathy

Next Previous
Trial Profile

EPPIC-Net EN21-01 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of 80 mg Daily of NRD135S.E1 Versus Placebo in Adult and Elderly Participants With Painful Diabetic Peripheral Neuropathy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nispomeben (Primary)
  • Indications Neuropathic pain
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EN21-01; SERENDIPITY-1

Most Recent Events

  • 02 Sep 2025 According to a Novaremed media release, the company is looking forward to completing analyses and sharing the results.
  • 02 Sep 2025 According to a Novaremed media release, topline Phase 2b data are expected in November 2025.
  • 02 Sep 2025 According to a Novaremed media release, status changed from recruiting to completed. The company announced the completion of the last patient last visit (LPLV) in the National Institutes of Health (NIH).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top